vs
Adaptive Biotechnologies Corp（ADPT）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Resolute Holdings Management, Inc.的季度营收约是Adaptive Biotechnologies Corp的1.6倍（$117.7M vs $71.7M），Resolute Holdings Management, Inc.净利率更高（-1.5% vs -18.9%，领先17.5%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $1.4M）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
ADPT vs RHLD — 直观对比
营收规模更大
RHLD
是对方的1.6倍
$71.7M
净利率更高
RHLD
高出17.5%
-18.9%
自由现金流更多
RHLD
多$187.8M
$1.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $117.7M |
| 净利润 | $-13.6M | $-1.7M |
| 毛利率 | 74.6% | 55.7% |
| 营业利润率 | -17.8% | 30.2% |
| 净利率 | -18.9% | -1.5% |
| 营收同比 | 51.0% | — |
| 净利润同比 | 59.7% | — |
| 每股收益（稀释后） | $-0.08 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTRHLD
| Q4 25 | $71.7M | $117.7M | ||
| Q3 25 | $94.0M | $120.9M | ||
| Q2 25 | $58.9M | $119.6M | ||
| Q1 25 | $52.4M | $103.9M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.4M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $41.9M | — |
净利润ADPTRHLD
| Q4 25 | $-13.6M | $-1.7M | ||
| Q3 25 | $9.5M | $-231.0K | ||
| Q2 25 | $-25.6M | $-611.0K | ||
| Q1 25 | $-29.9M | $-3.4M | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | — | ||
| Q2 24 | $-46.2M | — | ||
| Q1 24 | $-47.5M | — |
毛利率ADPTRHLD
| Q4 25 | 74.6% | 55.7% | ||
| Q3 25 | 80.7% | 59.0% | ||
| Q2 25 | 69.4% | 57.5% | ||
| Q1 25 | 67.6% | 52.5% | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 56.9% | — |
营业利润率ADPTRHLD
| Q4 25 | -17.8% | 30.2% | ||
| Q3 25 | 10.9% | 34.3% | ||
| Q2 25 | -42.5% | 34.0% | ||
| Q1 25 | -56.4% | 24.7% | ||
| Q4 24 | -71.3% | — | ||
| Q3 24 | -70.3% | — | ||
| Q2 24 | -109.6% | — | ||
| Q1 24 | -116.5% | — |
净利率ADPTRHLD
| Q4 25 | -18.9% | -1.5% | ||
| Q3 25 | 10.2% | -0.2% | ||
| Q2 25 | -43.5% | -0.5% | ||
| Q1 25 | -56.9% | -3.2% | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | — | ||
| Q2 24 | -107.0% | — | ||
| Q1 24 | -113.5% | — |
每股收益（稀释后）ADPTRHLD
| Q4 25 | $-0.08 | $-0.20 | ||
| Q3 25 | $0.06 | $-0.03 | ||
| Q2 25 | $-0.17 | $-0.07 | ||
| Q1 25 | $-0.20 | $-0.39 | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | — | ||
| Q1 24 | $-0.33 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | $218.8M | $6.5M |
| 总资产 | $512.7M | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资ADPTRHLD
| Q4 25 | $70.5M | $205.5M | ||
| Q3 25 | $55.0M | $148.0M | ||
| Q2 25 | $43.2M | $99.9M | ||
| Q1 25 | $50.6M | $71.0M | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $38.1M | — | ||
| Q2 24 | $59.8M | — | ||
| Q1 24 | $71.2M | — |
总债务ADPTRHLD
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADPTRHLD
| Q4 25 | $218.8M | $6.5M | ||
| Q3 25 | $204.4M | $10.8M | ||
| Q2 25 | $179.7M | $9.6M | ||
| Q1 25 | $190.4M | $8.9M | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | $223.8M | — | ||
| Q2 24 | $241.6M | — | ||
| Q1 24 | $274.9M | — |
总资产ADPTRHLD
| Q4 25 | $512.7M | $333.4M | ||
| Q3 25 | $490.6M | $293.2M | ||
| Q2 25 | $496.6M | $253.3M | ||
| Q1 25 | $510.9M | $214.3M | ||
| Q4 24 | $539.4M | — | ||
| Q3 24 | $558.5M | — | ||
| Q2 24 | $584.9M | — | ||
| Q1 24 | $620.3M | — |
负债/权益比ADPTRHLD
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $189.2M |
| 自由现金流率自由现金流/营收 | 2.0% | 160.8% |
| 资本支出强度资本支出/营收 | 0.9% | 5.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $313.2M |
8季度趋势，按日历期对齐
经营现金流ADPTRHLD
| Q4 25 | $2.1M | $196.1M | ||
| Q3 25 | $-7.1M | $59.6M | ||
| Q2 25 | $-12.4M | $48.9M | ||
| Q1 25 | $-28.5M | $18.4M | ||
| Q4 24 | $-12.5M | — | ||
| Q3 24 | $-27.1M | — | ||
| Q2 24 | $-17.3M | — | ||
| Q1 24 | $-38.4M | — |
自由现金流ADPTRHLD
| Q4 25 | $1.4M | $189.2M | ||
| Q3 25 | $-7.5M | $58.6M | ||
| Q2 25 | $-13.1M | $47.5M | ||
| Q1 25 | $-29.7M | $17.8M | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-27.4M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-39.9M | — |
自由现金流率ADPTRHLD
| Q4 25 | 2.0% | 160.8% | ||
| Q3 25 | -8.0% | 48.5% | ||
| Q2 25 | -22.2% | 39.7% | ||
| Q1 25 | -56.7% | 17.1% | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | — | ||
| Q2 24 | -44.1% | — | ||
| Q1 24 | -95.2% | — |
资本支出强度ADPTRHLD
| Q4 25 | 0.9% | 5.8% | ||
| Q3 25 | 0.4% | 0.8% | ||
| Q2 25 | 1.1% | 1.2% | ||
| Q1 25 | 2.4% | 0.6% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 4.0% | — | ||
| Q1 24 | 3.6% | — |
现金转化率ADPTRHLD
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RHLD
暂无分部数据
